- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03094169
AVID100 in Advanced Epithelial Carcinomas
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
On Day 1 of study, patients will receive study drug administered by 2-hour IV infusion. AVID100 will be administered once every 3 weeks (Q3W) with administration on Day 1 of the first week, followed by a 3-week recovery period. In Phase 2a AVID100 will be administered at a dose of 220 mg/m2.
Evidence of progressive disease at any point in the study will necessitate withdrawal of the patient from further participation so that alternative management of their malignancy may be considered. All patients will be followed to further evaluate safety as well as evidence of the anti-tumor effects of AVID100 in these selected patient populations. If anti-tumor activity is observed additional patients may be added to the planned Phase 2a patient populations to further characterize these effects.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Yale
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Start Midwest
-
-
New York
-
New York, New York, United States, 10029
- The Tisch Cancer Institute-Mt. Sinai
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase
-
-
Texas
-
Austin, Texas, United States, 78705
- Texas Oncology Midtown
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
Dallas, Texas, United States, 75246
- Texas Oncology-Baylor -Charles A. Sammons Cancer Center
-
McAllen, Texas, United States, 78503
- Texas Oncology McAllen
-
San Antonio, Texas, United States, 78217
- Texas Oncology NE San Antonio
-
Tyler, Texas, United States, 75702
- Texas Oncology Tyler
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (Phase 1):
- Patients with a documented (histologically- or cytologically-proven) solid tumor epithelial carcinoma that is locally advanced or metastatic
- Patients with a malignancy that is either refractory to standard therapy, or for which no standard therapy is available
- Patients with a malignancy that is currently not amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor
- Phase 1a Dose-Escalation Cohorts: Patients with measurable or non-measurable disease according to RECIST, v1.1 criteria. To include patients reasonably likely to express EGFR.
Inclusion Criteria (Phase 2a)
- Patients with measurable disease according to RECIST, v1.1 criteria.
- Patients with triple negative breast cancer who are either EGFR 2+ or EGFR 3+ by validated IHC assay.
- Patients with squamous non-small cell lung cancer who are EGFR 3+ by validated IHC assay.
- Patients with squamous cell carcinoma of the head and neck who are EGFR 3+ by validated IHC assay.
- Patients whose malignancy is either refractory to standard therapy, or for which no standard therapy is available
- Patients whose malignancy is currently not amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor
Patients to be Excluded (patients must not meet any of the following criteria Phase 1 only)
- Women who are pregnant or lactating. Women of child-bearing potential (WOCBP) and fertile men with WOCBP partner(s), not using and not willing to use a medically effective method of contraception.
- Patients with known central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required
- Patients with a malignancy other than that of epithelial origin
- Patients with hematologic abnormalities at baseline
- Patients with a significant cardiovascular disease or condition
- Patients with a significant ocular disease or condition
- Patients with a significant pulmonary disease or condition
- History of pneumonia within 6 months prior to the first study drug administration
- Patients with significant gastrointestinal (GI) abnormalities
- Patients with non-healing wounds on any part of the body
Patients to be Excluded (patients must not meet any of the following criteria Phase 2a only)
- Women who are pregnant or lactating. Women of child-bearing potential (WOCBP) and fertile men with WOCBP partner(s), not using and not willing to use a medically effective method of contraception.
- Patients with known central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required
- Patients with a malignancy other than EGFR-overexpressing triple negative breast cancer, squamous histology non-small cell lung cancer, or squamous cell carcinoma of the head and neck.
- Patients with hematologic abnormalities at baseline
- Patients with a significant cardiovascular disease or condition
- Patients with a significant ocular disease or condition
- Patients with a significant pulmonary disease or condition
- History of pneumonia within 6 months prior to the first study drug administration
- Patients with significant gastrointestinal (GI) abnormalities
- Patients with non-healing wounds on any part of the body
- Patients without measurable disease according to RECIST v1.1
- Patients with an active second malignancy within the last 2 years prior to entry
Drugs and Other Treatments to be Excluded
- Any antineoplastic agent for the primary malignancy (standard or investigational), without delayed toxicity, within 4 weeks, 5 plasma half-lives, or twice the duration of the biological effect, whichever is shortest, prior to first study drug administration and during study with the exception of: Nitrosoureas and nitrogen mustard within 6 weeks prior to first study drug administration and during study
- Any other investigational treatments during study. This includes participation in any medical device or other therapeutic intervention clinical trials.
- Radiotherapy for target lesions within 4 weeks prior to first study drug administration and during study
- Herbal preparations or related over-the-counter (OTC) preparations/supplements containing herbal ingredients aimed at treating the underlying malignancy within 2 weeks prior to first study drug administration and during study
- Strong inhibitors and/or inducers of cytochrome P450 (CYP) isoenzyme 3A4 within 2 weeks prior to first study drug administration and during study
- Immunosuppressive or systemic hormonal therapy within 2 weeks prior to first study drug administration and during study.
- Prophylactic use of hematopoietic growth factors within 1 week prior to first study drug administration and during Cycle 1 of study; thereafter prophylactic use of growth factors is allowed as clinically indicated
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose escalation
Minimum of 1 to 3 patients per dose cohort; approximately 4 dose cohorts to be evaluated to establish the Maximum tolerated dose.
|
AVID100 is administered once every 3 weeks
|
Experimental: Phase 2a Triple Negative Breast Cancer
Addition of up to 15 patients in each of 2 subpopulations of patients with triple negative breast cancer (30 total).
One group of 15 patients will have 3+ EGFR over-expression.
The second group will have 2+ EGFR over-expression.
|
AVID100 is administered once every 3 weeks
|
Experimental: Phase 2a Head and Neck Carcinoma
Addition of 15 patients with squamous head and neck carcinoma.
Patients will have 3+ EGFR over-expression.
|
AVID100 is administered once every 3 weeks
|
Experimental: Phase 2a Non-Small Cell Lung Carcinoma
Addition of 15 patients with squamous histology non-small cell lung carcinoma.
Patients will have 3+ EGFR over-expression
|
AVID100 is administered once every 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1a: Determine safety and tolerability of AVID100
Time Frame: 6 months
|
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
|
6 months
|
Phase 2a: Evaluation of the preliminary antineoplastic effects of AVID100
Time Frame: 18 months
|
Number of participants with objective response or stable disease
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK Profile of Total Antibody
Time Frame: 18 months
|
Characterization of the pharmacokinetic profile of total antibody
|
18 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AVID100-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on AVID100 IV
-
Taipei City HospitalNot yet recruitingAcute Flank PainTaiwan
-
Eli Lilly and CompanyCompletedPsoriasisUnited States
-
Healthgen Biotechnology Corp.RecruitingEmphysema Secondary to Congenital AATDUnited States
-
Kyowa Kirin Co., Ltd.Terminated
-
Healthgen Biotechnology Corp.Completed
-
Eli Lilly and CompanyCompletedAlzheimer DiseaseUnited States, Japan
-
Asir John SamuelMaharishi Markendeswar University (Deemed to be University)RecruitingAcute Coronary SyndromeIndia
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
C. R. BardCompletedVascular Access ComplicationUnited States
-
WockhardtCompletedBioavailabilityUnited States